Daniela Fruttini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniela Fruttini has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Marco Lupidi
Department of Experimental and Clinical Medicine, Eye Clinic, Polytechnic University of Marche, Ancona, Italy
5 shared publications - Jay Chhablani
UPMC Eye Center, University of Pittsburgh, Pittsburgh, Pennsylvania
4 shared publications - Lorenzo Mangoni
Eye Clinic, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, 60126 Ancona, Italy
4 shared publications - Alessio Muzi
Eye Clinic, Humanitas Gradenigo, 10153 Turin, Italy
3 shared publications - Carlo Cagini
Department of Medicine and Surgery, Ophthalmology Section, S. Maria Della Misericordia Hospital, University of Perugia, Perugia, Italy
3 shared publications - Cesare Mariotti
Eye Clinic, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, 60126 Ancona, Italy
3 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5701
Functional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathy
Background/Objectives: To evaluate whether the combination of oral eplerenone and half-dose full-fluence photodynamic therapy (HD-FF PDT) provides greater efficacy than HD-FF PDT alone in persistent central serous chorioretinopathy (CSCR). Methods: This monocentric, retrospective, observational study included patients with persistent (>6 months) simple or complex CSCR who had previously undergone either half-dose full-fluence photodynamic therapy (HD-FF PDT) alone or HD-FF PDT combined with oral eplerenone as part of routine clinical practice between September 2024 and March 2025. Functional and morphological data collected at baseline and at 1, 3, and 6 months after treatment were retrospectively reviewed. An artificial intelligence–based algorithm was used to analyze OCT scans, quantifying subretinal and intraretinal fluid volumes (SRFV, IRFV) and assessing ellipsoid zone and external limiting membrane integrity, hyperreflective foci, subfoveal choroidal thickness (SCT), and central macular thickness (CMT). Results: Fifty patients (53 eyes; mean age 52 years) were included, with no significant baseline differences between groups. Best-corrected visual acuity improved more significantly in Group B at 1 and 6 months (p = 0.032 and p = 0.009, respectively). At 6 months, subretinal fluid volume (SRFV), quantified by AI-based OCT analysis, was significantly lower in the combined therapy group (p = 0.014). An AI-defined complete resolution of subretinal fluid (SRFV < 0.010 mm3) was achieved more frequently in Group B than in Group A (77% vs. 22%, p = 0.001). Conclusions: Although HD-FF PDT remains the standard treatment for persistent CSCR, adjunctive therapy with the mineralocorticoid receptor antagonist eplerenone may enhance subretinal fluid reabsorption and improve mid-term anatomical and functional outcomes.
- 21 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5701
Open AccessFunctional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathy
Background/Objectives: To evaluate whether the combination of oral eplerenone and half-dose full-fluence photodynamic therapy (HD-FF PDT) provides greater efficacy than HD-FF PDT alone in persistent central serous chorioretinopathy (CSCR). Methods: This monocentric, retrospective, observational study included patients with persistent (>6 months) simple or complex CSCR who had previously undergone either half-dose full-fluence photodynamic therapy (HD-FF PDT) alone or HD-FF PDT combined with oral eplerenone as part of routine clinical practice between September 2024 and March 2025. Functional and morphological data collected at baseline and at 1, 3, and 6 months after treatment were retrospectively reviewed. An artificial intelligence–based algorithm was used to analyze OCT scans, quantifying subretinal and intraretinal fluid volumes (SRFV, IRFV) and assessing ellipsoid zone and external limiting membrane integrity, hyperreflective foci, subfoveal choroidal thickness (SCT), and central macular thickness (CMT). Results: Fifty patients (53 eyes; mean age 52 years) were included, with no significant baseline differences between groups. Best-corrected visual acuity improved more significantly in Group B at 1 and 6 months (p = 0.032 and p = 0.009, respectively). At 6 months, subretinal fluid volume (SRFV), quantified by AI-based OCT analysis, was significantly lower in the combined therapy group (p = 0.014). An AI-defined complete resolution of subretinal fluid (SRFV < 0.010 mm3) was achieved more frequently in Group B than in Group A (77% vs. 22%, p = 0.001). Conclusions: Although HD-FF PDT remains the standard treatment for persistent CSCR, adjunctive therapy with the mineralocorticoid receptor antagonist eplerenone may enhance subretinal fluid reabsorption and improve mid-term anatomical and functional outcomes.
- Open Access
- 24 June 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (7) , 120
Promoting Physical Activity and Reducing Sedentary Behavior in Adults with Type 2 Diabetes: Study Protocol of the DIA/01 Randomized Trial
Background: Sedentary behavior is a major modifiable risk factor for chronic metabolic disorders, particularly type 2 diabetes mellitus (T2DM). Despite recommendations promoting regular physical activity (PA), adherence remains low. DIA/01 is a multidisciplinary study designed to promote healthy lifestyles for the prevention and management of T2DM, supporting healthcare systems. Methods: A total of 123 adults with T2DM diagnosed will be enrolled at the Diabetes Center of the University Hospital of Perugia throughout 2025. Inclusion criteria are age 25–80 years, ability to walk independently, being inactive, and BMI 18.5–40 kg/m2. Exclusion criteria include severe cardiovascular, central nervous system, or musculoskeletal diseases contraindicating PA. Participants will be randomized into three groups: (1) standard care (SC); (2) SC plus theoretical PA counseling (TCPA); and (3) SC plus TCPA plus a 3-month supervised mixed exercise program. The assessment, conducted at baseline and at 6 and 12 months, includes total weekly PA (WPA) time, using IPAQ-SF and actigraphy. Moreover, glycated hemoglobin, sedentary time (ST), functional capacity, body composition, cardiometabolic risk factors, dietary adherence, perceived barriers and willingness to initiate PA, readiness to change, health-related quality of life, and sleep quality will be studied. This study is registered in the Clinical Trials Registry on 13 May 2026, with the identifier NCT07583355. Conclusions: Participants in groups (2) and (3) are expected to show greater improvements in WPA, reductions in ST, and favorable changes in metabolic and functional outcomes compared with SC. This approach may support long-term engagement in regular PA and contribute to improving the clinical management of T2DM.
- 24 June 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (7) , 120
Open AccessPromoting Physical Activity and Reducing Sedentary Behavior in Adults with Type 2 Diabetes: Study Protocol of the DIA/01 Randomized Trial
Background: Sedentary behavior is a major modifiable risk factor for chronic metabolic disorders, particularly type 2 diabetes mellitus (T2DM). Despite recommendations promoting regular physical activity (PA), adherence remains low. DIA/01 is a multidisciplinary study designed to promote healthy lifestyles for the prevention and management of T2DM, supporting healthcare systems. Methods: A total of 123 adults with T2DM diagnosed will be enrolled at the Diabetes Center of the University Hospital of Perugia throughout 2025. Inclusion criteria are age 25–80 years, ability to walk independently, being inactive, and BMI 18.5–40 kg/m2. Exclusion criteria include severe cardiovascular, central nervous system, or musculoskeletal diseases contraindicating PA. Participants will be randomized into three groups: (1) standard care (SC); (2) SC plus theoretical PA counseling (TCPA); and (3) SC plus TCPA plus a 3-month supervised mixed exercise program. The assessment, conducted at baseline and at 6 and 12 months, includes total weekly PA (WPA) time, using IPAQ-SF and actigraphy. Moreover, glycated hemoglobin, sedentary time (ST), functional capacity, body composition, cardiometabolic risk factors, dietary adherence, perceived barriers and willingness to initiate PA, readiness to change, health-related quality of life, and sleep quality will be studied. This study is registered in the Clinical Trials Registry on 13 May 2026, with the identifier NCT07583355. Conclusions: Participants in groups (2) and (3) are expected to show greater improvements in WPA, reductions in ST, and favorable changes in metabolic and functional outcomes compared with SC. This approach may support long-term engagement in regular PA and contribute to improving the clinical management of T2DM.
- Open Access
- 17 June 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (6)
CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies treatment
Aim: Calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) play a crucial role in migraine pathophysiology. In recent years, anti-CGRP(R) monoclonal antibodies (mAbs) have emerged as the first targeted and highly effective therapy for migraine. This study aimed to assess any changes in plasma CGRP levels following prophylactic treatment with anti-CGRP(R) mAbs and to compare CGRP dynamics between anti-receptor (erenumab) and anti-ligand (galcanezumab, fremanezumab) therapies. Secondary objectives were: (i) to evaluate changes in VIP and PACAP plasma levels following treatment with anti-CGRP(R) mAbs and (ii) to investigate whether baseline or post-treatment plasma levels of CGRP, VIP and PACAP were associated with clinical response to anti-CGRP(R) monoclonal antibody therapy. Methods: Between February 2022 and February 2023, we enrolled 56 migraine patients who initiated prophylaxis with either erenumab (26 patients), galcanezumab (16 patients) or fremanezumab (14 patients). Responders were defined as those achieving a ≥50% reduction in monthly migraine days after six months. Blood samples were collected at baseline and at each follow-up visit (baseline, T0; three months, T1; six months, T2; 12 months, T3). Plasma levels of CGRP, VIP and PACAP were measured using a validated radioimmunoassay and commercially available enzyme-linked immunosorbent assay kits. Results: Overall, 80.3% (45 out of 56) of patients responded to anti-CGRP(R) mAbs. No correlation was found between baseline CGRP, VIP and PACAP plasma levels and clinical response to anti-CGRP(R) mAbs therapy. Regarding CGRP trend, significant differences were found between patients treated with the anti-receptor monoclonal antibody (erenumab) and those receiving anti-ligand therapies. In patients treated with erenumab, CGRP levels did not show a significant change over the treatment period (T1–T3), whereas, in the galcanezumab group, CGRP levels significantly decreased as early as T1 ( p < 0.01). CGRP longitudinal assessment of the fremanezumab group were excluded due to assay interference with the drug. VIP and PACAP plasma levels remained stable over time for all treatments, with no significant differences between responders and non-responders. Conclusions: Galcanezumab reduced CGRP plasmatic levels already after three months, whereas erenumab did not affect significantly CGRP plasmatic levels. VIP and PACAP levels were not influenced by the therapy.
- 17 June 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (6)
Open AccessCGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies treatment
Aim: Calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) play a crucial role in migraine pathophysiology. In recent years, anti-CGRP(R) monoclonal antibodies (mAbs) have emerged as the first targeted and highly effective therapy for migraine. This study aimed to assess any changes in plasma CGRP levels following prophylactic treatment with anti-CGRP(R) mAbs and to compare CGRP dynamics between anti-receptor (erenumab) and anti-ligand (galcanezumab, fremanezumab) therapies. Secondary objectives were: (i) to evaluate changes in VIP and PACAP plasma levels following treatment with anti-CGRP(R) mAbs and (ii) to investigate whether baseline or post-treatment plasma levels of CGRP, VIP and PACAP were associated with clinical response to anti-CGRP(R) monoclonal antibody therapy. Methods: Between February 2022 and February 2023, we enrolled 56 migraine patients who initiated prophylaxis with either erenumab (26 patients), galcanezumab (16 patients) or fremanezumab (14 patients). Responders were defined as those achieving a ≥50% reduction in monthly migraine days after six months. Blood samples were collected at baseline and at each follow-up visit (baseline, T0; three months, T1; six months, T2; 12 months, T3). Plasma levels of CGRP, VIP and PACAP were measured using a validated radioimmunoassay and commercially available enzyme-linked immunosorbent assay kits. Results: Overall, 80.3% (45 out of 56) of patients responded to anti-CGRP(R) mAbs. No correlation was found between baseline CGRP, VIP and PACAP plasma levels and clinical response to anti-CGRP(R) mAbs therapy. Regarding CGRP trend, significant differences were found between patients treated with the anti-receptor monoclonal antibody (erenumab) and those receiving anti-ligand therapies. In patients treated with erenumab, CGRP levels did not show a significant change over the treatment period (T1–T3), whereas, in the galcanezumab group, CGRP levels significantly decreased as early as T1 ( p < 0.01). CGRP longitudinal assessment of the fremanezumab group were excluded due to assay interference with the drug. VIP and PACAP plasma levels remained stable over time for all treatments, with no significant differences between responders and non-responders. Conclusions: Galcanezumab reduced CGRP plasmatic levels already after three months, whereas erenumab did not affect significantly CGRP plasmatic levels. VIP and PACAP levels were not influenced by the therapy.
- 13 June 2026
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 34 (6) , 1-6
Exudative Retinal Detachment in Inflammatory Ocular Diseases: Epidemiology, Clinical and Imaging Characteristics in Two Referral Hospitals in Italy
The aim of the study was to analyze the epidemiological, clinical and imaging characteristics of patients with inflammatory exudative retinal detachment (ERD). This multicenter, retrospective, observational study enrolled patients with a diagnosis of an inflammatory ocular disease associated with ERD. In all patients a complete ophthalmological evaluation was performed, with best-corrected visual acuity (BCVA), automated refraction, slit lamp biomicroscopy, intraocular pressure (IOP), fundus examination, optic coherence tomography (OCT) scan, color fundus photography, fluorescein angiography (FA) and indocyanine green angiography (ICGA). ERD was located (posterior pole, peripheral retina or both) with imaging, and the presence or absence of subfoveal neuroepithelial detachment, retinal pigment epithelium (RPE) detachment, epiretinal membrane (ERM), and macular edema (ME) were documented. 130 patients were enrolled, with a mean age of 52.14 ± 20.69 years. The most representative diagnosis was Vogt-Koyanagi-Harada (VKH) disease (23.85%), followed by Sarcoidosis (16.15%), Tuberculosis (13.08%) and Posterior Scleritis (PS) (9.23%). The principal location of ERD in the 165 enrolled eyes was in the posterior pole. In VKH, ERD was located at the posterior pole in 45 eyes, with 85.71% of subfoveal neuroepithelial detachment and choroidal granulomas in 87.76% of eyes. In PS a posterior pole location of ERD was found in 66.67% of eyes, with 83.33% of subfoveal neuroepithelial detachment and no choroidal granulomas. ERD is most frequently associated with VKH disease and the predominant localization is at the posterior pole, which occurs in the setting of posterior uveitis, panuveitis, and/or scleritis.
- 13 June 2026
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 34 (6) , 1-6
Exudative Retinal Detachment in Inflammatory Ocular Diseases: Epidemiology, Clinical and Imaging Characteristics in Two Referral Hospitals in Italy
The aim of the study was to analyze the epidemiological, clinical and imaging characteristics of patients with inflammatory exudative retinal detachment (ERD). This multicenter, retrospective, observational study enrolled patients with a diagnosis of an inflammatory ocular disease associated with ERD. In all patients a complete ophthalmological evaluation was performed, with best-corrected visual acuity (BCVA), automated refraction, slit lamp biomicroscopy, intraocular pressure (IOP), fundus examination, optic coherence tomography (OCT) scan, color fundus photography, fluorescein angiography (FA) and indocyanine green angiography (ICGA). ERD was located (posterior pole, peripheral retina or both) with imaging, and the presence or absence of subfoveal neuroepithelial detachment, retinal pigment epithelium (RPE) detachment, epiretinal membrane (ERM), and macular edema (ME) were documented. 130 patients were enrolled, with a mean age of 52.14 ± 20.69 years. The most representative diagnosis was Vogt-Koyanagi-Harada (VKH) disease (23.85%), followed by Sarcoidosis (16.15%), Tuberculosis (13.08%) and Posterior Scleritis (PS) (9.23%). The principal location of ERD in the 165 enrolled eyes was in the posterior pole. In VKH, ERD was located at the posterior pole in 45 eyes, with 85.71% of subfoveal neuroepithelial detachment and choroidal granulomas in 87.76% of eyes. In PS a posterior pole location of ERD was found in 66.67% of eyes, with 83.33% of subfoveal neuroepithelial detachment and no choroidal granulomas. ERD is most frequently associated with VKH disease and the predominant localization is at the posterior pole, which occurs in the setting of posterior uveitis, panuveitis, and/or scleritis.
- Open Access
Integrating Nutrition and Physical Activity into the EXEMIG/01 Interdisciplinary Model for Chronic and High-Frequency Migraine
Background: Migraine (MIG) management guidelines support a comprehensive approach combining medication, therapeutic patient education (TPE), behavioral strategies, lifestyle changes, diet, and physical activity (PA). Objective: To present an innovative interdisciplinary outpatient model for individuals with MIG, focusing on PA, sedentary behavior, eating habits (EH), metabolic health, temporomandibular disorders, and postural dysfunctions. Design: A randomized controlled trial will enroll 200 adults with MIG over two years. Inclusion criteria are chronic MIG (≥15 attacks/month for ≥3 months) or high-frequency episodic MIG (8–14 attacks/month), physical inactivity, and independent walking ability. Exclusion criteria include contraindications to PA and lack of informed consent. Participants will be randomized to standard care (SC) or an intervention group receiving TPE plus three months of supervised exercise (EXE). All participants will receive an informational brochure with nutritional tips (included in SC) and undergo: (1) neurological examination, (2) validated questionnaires, (3) kinesiological and postural assessment, and (4) gnathological evaluation. The primary outcome is change in monthly MIG frequency at 6 and 12 months; additional outcomes include disability, quality of life, and intensity of MIG, PA levels, sedentary behavior, medication use, EH, functional capabilities, postural parameters, and temporomandibular disorder-related variables. Results: Hypothetically, the intervention may reduce monthly MIG frequency by approximately 15–20% relative to baseline. Improvements may also occur in disability, quality of life, medication use, lifestyle behaviors, and psychological and cardiometabolic parameters. Conclusions: This trial will evaluate whether adding supervised EXE and TPE to SC may improve MIG outcomes compared with SC alone, supporting a comprehensive management strategy.
Open AccessIntegrating Nutrition and Physical Activity into the EXEMIG/01 Interdisciplinary Model for Chronic and High-Frequency Migraine
Background: Migraine (MIG) management guidelines support a comprehensive approach combining medication, therapeutic patient education (TPE), behavioral strategies, lifestyle changes, diet, and physical activity (PA). Objective: To present an innovative interdisciplinary outpatient model for individuals with MIG, focusing on PA, sedentary behavior, eating habits (EH), metabolic health, temporomandibular disorders, and postural dysfunctions. Design: A randomized controlled trial will enroll 200 adults with MIG over two years. Inclusion criteria are chronic MIG (≥15 attacks/month for ≥3 months) or high-frequency episodic MIG (8–14 attacks/month), physical inactivity, and independent walking ability. Exclusion criteria include contraindications to PA and lack of informed consent. Participants will be randomized to standard care (SC) or an intervention group receiving TPE plus three months of supervised exercise (EXE). All participants will receive an informational brochure with nutritional tips (included in SC) and undergo: (1) neurological examination, (2) validated questionnaires, (3) kinesiological and postural assessment, and (4) gnathological evaluation. The primary outcome is change in monthly MIG frequency at 6 and 12 months; additional outcomes include disability, quality of life, and intensity of MIG, PA levels, sedentary behavior, medication use, EH, functional capabilities, postural parameters, and temporomandibular disorder-related variables. Results: Hypothetically, the intervention may reduce monthly MIG frequency by approximately 15–20% relative to baseline. Improvements may also occur in disability, quality of life, medication use, lifestyle behaviors, and psychological and cardiometabolic parameters. Conclusions: This trial will evaluate whether adding supervised EXE and TPE to SC may improve MIG outcomes compared with SC alone, supporting a comprehensive management strategy.
- 17 February 2026
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 34 (3) , 565-571
Epidemiology of Uveitis and Extra-Uveal Inflammation in a Referral Center in Central Italy
The epidemiology of uveitis remains highly variable, influenced by geographic location, genetic predisposition, environmental conditions, and socioeconomic context leading to significant differences in the distribution of clinical forms. The aim of this report was to analyse the epidemiological profile of uveitis at the tertiary referral center in Italy, providing a comprehensive overview of prevalence, clinical classifications, and etiological diagnoses. A retrospective study had been performed in a reference uveitis center in Italy, collecting data from February 2019 to December 2024. Demographic data, aetiology diagnosis and clinical characteristic were reported. Study enrolled 752 patients with ocular inflammation, 623 of whom had uveitis. Female represented the 58.51%, while the majority of patients were Caucasian (92.15%). Mean age was 51 years with middle-aged group represented the 68.75%. Noninfectious, including idiopathic forms, was the main aetiology (77.13%), followed by infectious (22.87%). Anterior uveitis (AU) was the 56.34%, posterior uveitis the 26.48%, panuveitis 11.57% and intermediate (IU) 5.61%. A statistically significant association was found between the aetiology and the localization (p < 0.0001). Herpetic infectious, HLA-B27-related, Fuchs, Toxoplasma and Sarcoidosis represented the main diagnosis. The study documented the epidemiology trend of uveitis, comparing with other European studies. Females and middle-aged group were the most frequent involvement groups. Noninfectious disease represented the primary etiologic cause. The AU was the main localization of inflammation. These results contribute to a better understanding of the distribution of uveitis in the region and help improve diagnostic and therapeutic processes.
- 17 February 2026
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 34 (3) , 565-571
Epidemiology of Uveitis and Extra-Uveal Inflammation in a Referral Center in Central Italy
The epidemiology of uveitis remains highly variable, influenced by geographic location, genetic predisposition, environmental conditions, and socioeconomic context leading to significant differences in the distribution of clinical forms. The aim of this report was to analyse the epidemiological profile of uveitis at the tertiary referral center in Italy, providing a comprehensive overview of prevalence, clinical classifications, and etiological diagnoses. A retrospective study had been performed in a reference uveitis center in Italy, collecting data from February 2019 to December 2024. Demographic data, aetiology diagnosis and clinical characteristic were reported. Study enrolled 752 patients with ocular inflammation, 623 of whom had uveitis. Female represented the 58.51%, while the majority of patients were Caucasian (92.15%). Mean age was 51 years with middle-aged group represented the 68.75%. Noninfectious, including idiopathic forms, was the main aetiology (77.13%), followed by infectious (22.87%). Anterior uveitis (AU) was the 56.34%, posterior uveitis the 26.48%, panuveitis 11.57% and intermediate (IU) 5.61%. A statistically significant association was found between the aetiology and the localization (p < 0.0001). Herpetic infectious, HLA-B27-related, Fuchs, Toxoplasma and Sarcoidosis represented the main diagnosis. The study documented the epidemiology trend of uveitis, comparing with other European studies. Females and middle-aged group were the most frequent involvement groups. Noninfectious disease represented the primary etiologic cause. The AU was the main localization of inflammation. These results contribute to a better understanding of the distribution of uveitis in the region and help improve diagnostic and therapeutic processes.
- Open Access
- 28 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2312
Vascular Perfusion Variability in Diabetic Retinopathy: A Sequential Interscan Optical Coherence Tomography Angiography Assessment
Background/Objectives: The aim of this study was to quantify the interscan variability of vascular perfusion in patients with diabetic retinopathy (DR) using sequential optical coherence tomography angiography (OCT-A) scans. Methods: Patients with low-grade DR (DRSS score 20) underwent five sequential OCT-A imaging sessions. Vessel perfusion density (VPD) values of the superficial capillary plexus (SCP), intermediate capillary plexus (ICP), deep capillary plexus (DCP), and choriocapillaris (CC) were computed using ImageJ Version 1.54 software via a binarization process. The binarized images were analyzed to compute VPD using vessel density plugins. Inter-session variability was assessed using the coefficient of variation (CV) and intraclass correlation coefficient (ICC). The results were compared with an age-matched group of healthy controls. Results: A total of 16 eyes from 16 patients with DR (6 females, 37.5%) and 16 eyes from healthy controls (6 females, 37.5%) were included. Mean VPD values for SCP, ICP, DCP, and CC in patients with DR were 23.64, 13.64, 15.31, and 36.57, respectively. Corresponding values for the healthy subjects were 37.65, 23.32, 22.05, and 49.00, respectively. No significant differences were found in VPD across consecutive scanning sessions (p > 0.05) in either group. However, significant differences in VPD were observed between patients who were healthy and patients with diabetes. Conclusions: Sequential OCT-A imaging demonstrated no significant inter-session variability in both healthy subjects and subjects with diabetes. The Spectralis OCT-A system showed high reliability for imaging both healthy and diseased conditions.
- 28 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2312
Open AccessVascular Perfusion Variability in Diabetic Retinopathy: A Sequential Interscan Optical Coherence Tomography Angiography Assessment
Background/Objectives: The aim of this study was to quantify the interscan variability of vascular perfusion in patients with diabetic retinopathy (DR) using sequential optical coherence tomography angiography (OCT-A) scans. Methods: Patients with low-grade DR (DRSS score 20) underwent five sequential OCT-A imaging sessions. Vessel perfusion density (VPD) values of the superficial capillary plexus (SCP), intermediate capillary plexus (ICP), deep capillary plexus (DCP), and choriocapillaris (CC) were computed using ImageJ Version 1.54 software via a binarization process. The binarized images were analyzed to compute VPD using vessel density plugins. Inter-session variability was assessed using the coefficient of variation (CV) and intraclass correlation coefficient (ICC). The results were compared with an age-matched group of healthy controls. Results: A total of 16 eyes from 16 patients with DR (6 females, 37.5%) and 16 eyes from healthy controls (6 females, 37.5%) were included. Mean VPD values for SCP, ICP, DCP, and CC in patients with DR were 23.64, 13.64, 15.31, and 36.57, respectively. Corresponding values for the healthy subjects were 37.65, 23.32, 22.05, and 49.00, respectively. No significant differences were found in VPD across consecutive scanning sessions (p > 0.05) in either group. However, significant differences in VPD were observed between patients who were healthy and patients with diabetes. Conclusions: Sequential OCT-A imaging demonstrated no significant inter-session variability in both healthy subjects and subjects with diabetes. The Spectralis OCT-A system showed high reliability for imaging both healthy and diseased conditions.
- Open Access
- 22 March 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (7) , 702
Correlations Between Gender, Age, and Occupational Factors on the Work Ability Index Among Healthcare Professionals
Background: The Work Ability Index (WAI) measures how well employees’ abilities match their job demands. This study assessed the WAI among health workers and explored how age, gender, and job roles affected it. The research was conducted in a central Italian hospital, with a focus on health workers undergoing health surveillance between September 2020 and April 2021. Methods: Data were collected using validated questionnaires that assessed the WAI and risk factors for metabolic syndrome among participants. Demographic information, including age, gender, and occupation, was also obtained. The study involved 1847 health workers, with an average age of 43 years, predominantly women (67.6%). Occupational categories included administrative staff, nurses/healthcare workers (HCWs)/midwives, physicians, and healthcare technicians. Statistical analyses, such as t-tests, ANOVA, and chi-squared tests, were performed to explore the relationships between WAI scores and demographic/occupational variables. Results: The study suggested a relationship between WAI scores and gender, age, and occupation. Men workers exhibited higher mean WAI scores than women workers, while older workers (>55 years) had lower WAI scores compared with their younger counterparts. WAI scores varied by job role, with physicians scoring the highest. Conclusions: The findings suggested that demographic and occupational factors were associated with variations in work ability among health workers. These findings can help improve workforce management, occupational health, and research on aging workers. However, it is important to acknowledge the limitations of this study. Given its cross-sectional design, causal inferences cannot be established, and further longitudinal research is needed to confirm these findings and explore potential causal relationships.
- 22 March 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (7) , 702
Open AccessCorrelations Between Gender, Age, and Occupational Factors on the Work Ability Index Among Healthcare Professionals
Background: The Work Ability Index (WAI) measures how well employees’ abilities match their job demands. This study assessed the WAI among health workers and explored how age, gender, and job roles affected it. The research was conducted in a central Italian hospital, with a focus on health workers undergoing health surveillance between September 2020 and April 2021. Methods: Data were collected using validated questionnaires that assessed the WAI and risk factors for metabolic syndrome among participants. Demographic information, including age, gender, and occupation, was also obtained. The study involved 1847 health workers, with an average age of 43 years, predominantly women (67.6%). Occupational categories included administrative staff, nurses/healthcare workers (HCWs)/midwives, physicians, and healthcare technicians. Statistical analyses, such as t-tests, ANOVA, and chi-squared tests, were performed to explore the relationships between WAI scores and demographic/occupational variables. Results: The study suggested a relationship between WAI scores and gender, age, and occupation. Men workers exhibited higher mean WAI scores than women workers, while older workers (>55 years) had lower WAI scores compared with their younger counterparts. WAI scores varied by job role, with physicians scoring the highest. Conclusions: The findings suggested that demographic and occupational factors were associated with variations in work ability among health workers. These findings can help improve workforce management, occupational health, and research on aging workers. However, it is important to acknowledge the limitations of this study. Given its cross-sectional design, causal inferences cannot be established, and further longitudinal research is needed to confirm these findings and explore potential causal relationships.
- Open Access
- 1 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6580
Optical Coherence Tomography Study of Choroidal Response to Exercise-Induced Hypertension in Chronic Central Serous Chorioretinopathy
Background/Objectives: The aim of this study was to evaluate the choroidal vascular response using optical coherence tomography (OCT) in patients with chronic central serous chorioretinopathy (CSCR) during transient increases in blood pressure. Methods: This observational, case–control study enrolled chronic CSCR patients and age-matched healthy controls. OCT scans of the macula were performed at rest and during hand-grip (HG) isometric exercise. Mean ocular perfusion pressure (MOPP) and subfoveal choroidal thickness (SCT) were measured at baseline and during stress. Quantitative OCT assessment included the bright area (BA, stroma), dark area (DA, vascular lumen), and total choroidal area (CA). The choroidal vascularity index (CVI) was calculated as DA/CA to assess vascular response to stress. A comparative analysis between CSCR patients and controls was conducted. Conclusions: MOPP was significantly higher (p = 0.008) at baseline in CSCR patients and further increased under stress compared to controls. SCT and CA were both significantly higher in CSCR patients than in healthy subjects at rest and under stress (p < 0.001), but no change occurred after HG. A significant decrease in CVI (p = 0.005) was noted in controls under stress, but not in CSCR patients. Additionally, a negative correlation between CVI and MOPP was found in healthy subjects (−0.648; p = 0.043). The study demonstrated a choroidal vasoconstrictive response to stress in healthy subjects, as evidenced by a decrease in CVI, but not in CSCR patients. This suggests that CSCR patients may experience impaired choroidal blood flow regulation, resulting in potentially higher perfusion pressures during stress without compensatory vasoconstriction, potentially affecting the choriocapillaris.
- 1 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6580
Open AccessOptical Coherence Tomography Study of Choroidal Response to Exercise-Induced Hypertension in Chronic Central Serous Chorioretinopathy
Background/Objectives: The aim of this study was to evaluate the choroidal vascular response using optical coherence tomography (OCT) in patients with chronic central serous chorioretinopathy (CSCR) during transient increases in blood pressure. Methods: This observational, case–control study enrolled chronic CSCR patients and age-matched healthy controls. OCT scans of the macula were performed at rest and during hand-grip (HG) isometric exercise. Mean ocular perfusion pressure (MOPP) and subfoveal choroidal thickness (SCT) were measured at baseline and during stress. Quantitative OCT assessment included the bright area (BA, stroma), dark area (DA, vascular lumen), and total choroidal area (CA). The choroidal vascularity index (CVI) was calculated as DA/CA to assess vascular response to stress. A comparative analysis between CSCR patients and controls was conducted. Conclusions: MOPP was significantly higher (p = 0.008) at baseline in CSCR patients and further increased under stress compared to controls. SCT and CA were both significantly higher in CSCR patients than in healthy subjects at rest and under stress (p < 0.001), but no change occurred after HG. A significant decrease in CVI (p = 0.005) was noted in controls under stress, but not in CSCR patients. Additionally, a negative correlation between CVI and MOPP was found in healthy subjects (−0.648; p = 0.043). The study demonstrated a choroidal vasoconstrictive response to stress in healthy subjects, as evidenced by a decrease in CVI, but not in CSCR patients. This suggests that CSCR patients may experience impaired choroidal blood flow regulation, resulting in potentially higher perfusion pressures during stress without compensatory vasoconstriction, potentially affecting the choriocapillaris.
- Open Access
- 22 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (2) , 628
Novel Artificial Intelligence-Based Assessment of Imaging Biomarkers in Full-Thickness Macular Holes: Preliminary Data from a Pivotal Trial
Artificial intelligence (AI)- and deep learning (DL)-based systems have shown significant progress in the field of macular disorders, demonstrating high performance in detecting retinal fluid and assessing anatomical changes during disease progression. This study aimed to validate an AI algorithm for identifying and quantifying prognostic factors in visual recovery after macular hole (MH) surgery by analyzing major optical coherence tomography (OCT) biomarkers. This study included 20 patients who underwent vitrectomy for a full-thickness macular hole (FTMH). The mean diameter of the FTMH was measured at 285.36 ± 97.4 μm. The preoperative best-corrected visual acuity (BCVA) was 0.76 ± 0.06 logMAR, improving to 0.38 ± 0.16 postoperatively, with a statistically significant difference (p = 0.001). AI software was utilized to assess biomarkers, such as intraretinal fluid (IRF) and subretinal fluid (SRF) volume, external limiting membrane (ELM) and ellipsoid zone (EZ) integrity, and retinal hyperreflective foci (HRF). The AI analysis showed a significant decrease in IRF volume, from 0.08 ± 0.12 mm3 preoperatively to 0.01 ± 0.01 mm3 postoperatively. ELM interruption improved from 79% ± 18% to 34% ± 37% after surgery (p = 0.006), whereas EZ interruption improved from 80% ± 22% to 40% ± 36% (p = 0.007) postoperatively. Additionally, the study revealed a negative correlation between preoperative IRF volume and postoperative BCVA recovery, suggesting that greater preoperative fluid volumes may hinder visual improvement. The integrity of the ELM and EZ was found to be essential for postoperative visual acuity improvement, with their disruption negatively impacting visual recovery. The study highlights the potential of AI in quantifying OCT biomarkers for managing MHs and improving patient care.
- 22 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (2) , 628
Open AccessNovel Artificial Intelligence-Based Assessment of Imaging Biomarkers in Full-Thickness Macular Holes: Preliminary Data from a Pivotal Trial
Artificial intelligence (AI)- and deep learning (DL)-based systems have shown significant progress in the field of macular disorders, demonstrating high performance in detecting retinal fluid and assessing anatomical changes during disease progression. This study aimed to validate an AI algorithm for identifying and quantifying prognostic factors in visual recovery after macular hole (MH) surgery by analyzing major optical coherence tomography (OCT) biomarkers. This study included 20 patients who underwent vitrectomy for a full-thickness macular hole (FTMH). The mean diameter of the FTMH was measured at 285.36 ± 97.4 μm. The preoperative best-corrected visual acuity (BCVA) was 0.76 ± 0.06 logMAR, improving to 0.38 ± 0.16 postoperatively, with a statistically significant difference (p = 0.001). AI software was utilized to assess biomarkers, such as intraretinal fluid (IRF) and subretinal fluid (SRF) volume, external limiting membrane (ELM) and ellipsoid zone (EZ) integrity, and retinal hyperreflective foci (HRF). The AI analysis showed a significant decrease in IRF volume, from 0.08 ± 0.12 mm3 preoperatively to 0.01 ± 0.01 mm3 postoperatively. ELM interruption improved from 79% ± 18% to 34% ± 37% after surgery (p = 0.006), whereas EZ interruption improved from 80% ± 22% to 40% ± 36% (p = 0.007) postoperatively. Additionally, the study revealed a negative correlation between preoperative IRF volume and postoperative BCVA recovery, suggesting that greater preoperative fluid volumes may hinder visual improvement. The integrity of the ELM and EZ was found to be essential for postoperative visual acuity improvement, with their disruption negatively impacting visual recovery. The study highlights the potential of AI in quantifying OCT biomarkers for managing MHs and improving patient care.